Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Novo Nordisk A/S (NVO)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 110,447,560
  • Shares Outstanding, K 2,443,530
  • Annual Sales, $ 4,700 M
  • Annual Income, $ -4,737,560 K
  • 36-Month Beta 0.75
  • Price/Sales 6.62
  • Price/Cash Flow 17.90
  • Price/Book 15.15

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 3 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/18
See More
  • Average Estimate 0.59
  • Number of Estimates 2
  • High Estimate 0.61
  • Low Estimate 0.56
  • Prior Year 0.53
  • Growth Rate Est. (year over year) +11.32%

Price Performance

See More
Period Period Low Period High Performance
1-Month
43.12 +6.71%
on 11/15/18
46.66 -1.39%
on 11/30/18
+1.47 (+3.30%)
since 11/12/18
3-Month
41.23 +11.59%
on 10/11/18
49.11 -6.31%
on 09/13/18
-2.96 (-6.04%)
since 09/12/18
52-Week
41.23 +11.59%
on 10/11/18
58.37 -21.18%
on 01/23/18
-7.31 (-13.71%)
since 12/12/17

Most Recent Stories

More News
Novo Nordisk purchases Berkeley Lights' Beacon® Optofluidic platform for cell line development and antibody discovery

Berkeley Lights, Inc. and Novo Nordisk today announced that Novo Nordisk has purchased the Beacon® Optofluidic platform to accelerate workflows in cell line development and to use the platform for future...

NVO : 46.01 (+1.79%)
Global Insulin Delivery Devices Market Outlook to 2024 with Profiles of Novo Nordisk, Sanofi Aventis, Eli Lilly and Company & Merck & Co

The "Global Insulin Delivery Devices Market (By Type - Insulin Pen, Insulin Vial & Syringes and Insulin Pumps; By Region - Europe, North America & Asia Pacific) Market Outlook 2024" report has been...

NVO : 46.01 (+1.79%)
MRK : 78.01 (+1.17%)
LLY : 114.34 (-0.14%)
Worldwide Opportunity Outlook on the Anti-obesity Drugs Market to 2022 - Key Players are Eisai, Novo Nordisk and Vivus - ResearchAndMarkets.com

The "Global Anti-obesity Drugs Market 2018-2022" report has been added to ResearchAndMarkets.com's offering.

NVO : 46.01 (+1.79%)
MSD, MSD Animal Health and Novonordisk Egypt Awarded the Best Places To Work Certification in Egypt for 2018

MSD, MSD Animal Health and Novo Nordisk Egypt were awarded the Best Place To Work certification in Egypt for 2018, according to the annual Workplace research program. Best Places to Work program is an...

NVO : 46.01 (+1.79%)
MRK : 78.01 (+1.17%)
Provention Bio Joins the C-Path Type 1 Diabetes (T1D) Consortium

Provention Bio, Inc. (Nasdaq:PRVB), a clinical-stage biopharmaceutical company dedicated to sourcing, developing and commercializing novel therapeutics aimed at intercepting and preventing immune-mediated...

NVO : 46.01 (+1.79%)
PRVB : 2.66 (+4.51%)
Zafgen (ZFGN) Plunges as FDA Puts Hold on Diabetes Drug Trial

Zafgen's (ZFGN) stock plunges significantly as the FDA placed a clinical hold on the company's first trial on experimental diabetes drug, ZGN-1061.

NVO : 46.01 (+1.79%)
LLY : 114.34 (-0.14%)
ZFGN : 5.48 (+3.40%)
GILD : 68.14 (+0.62%)
IQVIA's Orchestrated Customer Engagement Selected by Novo Nordisk International Operations

IQVIA(TM) (NYSE:IQV) today announced that Novo Nordisk, a global healthcare company with nearly a century of innovation and leadership in diabetes care, has selected IQVIA's market-leading...

NVO : 46.01 (+1.79%)
CRM : 140.09 (+2.41%)
IQV : 122.34 (+0.69%)
Global Diabetes Drug Market Report 2018-2024 Featuring Novo Nordisk, Merck & Co, Eli Lilly, AstraZeneca, Johnson & Johnson & Boehringer Ingelheim

The "Diabetes Drug Market, Oral, Injection, Regions, and Companies" report has been added to ResearchAndMarkets.com's offering.

NVO : 46.01 (+1.79%)
MRK : 78.01 (+1.17%)
LLY : 114.34 (-0.14%)
Emisphere Development Update

Novo Nordisk announced the completion and results on Thursday, November 22 and Friday, November 23 regarding their Pioneer 9 and Pioneer 6 phase 3a trials, both conducted with oral semaglutide, a once-daily...

EMIS : 2.4200 (-1.43%)
NVO : 46.01 (+1.79%)
Oral semaglutide demonstrates favourable cardiovascular safety profile and significant reduction in cardiovascular death and all-cause mortality in people with type 2 diabetes in the PIONEER 6 trial

Bagsvaerd, Denmark, 23 November 2018 - Novo Nordisk today announced the headline results from the last global phase 3a trial, PIONEER 6, for oral semaglutide, an investigational GLP-1 analogue taken once...

NVO : 46.01 (+1.79%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 16% Buy with a Strengthening short term outlook on maintaining the current direction.

Longer term, the trend strength is Minimum.

See More Share

Trade NVO with:

Business Summary

Novo Nordisk is a world leader in insulin and diabetes care and also manufactures and markets a variety of other pharmaceutical products. Furthermore the company is the world's largest producer of industrial enzyme products. The company believes that everyone must care for the environment and our natural...

See More

Key Turning Points

2nd Resistance Point 46.65
1st Resistance Point 46.33
Last Price 46.01
1st Support Level 45.69
2nd Support Level 45.38

See More

52-Week High 58.37
Fibonacci 61.8% 51.82
Fibonacci 50% 49.80
Fibonacci 38.2% 47.78
Last Price 46.01
52-Week Low 41.23

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar